Welcome Bayer


The approval of the non-vitamin K antagonist oral anticoagulants (NOACs) a decade ago changed our approach to the treatment and prevention of venous thromboembolism (VTE) considerably.

We are still learning about the management of VTE, and questions remain in challenging clinical scenarios. For example how to manage patients with cancer-associated thrombosis (CAT) with NOACs?

To answer to this question Bayer is supporting an extended program of trials. Recent data releases look set to change practice and our understanding of the use of NOACs in CAT treatment grows. In addition we are expecting a number of additional key trials (CASTA DIVA, COSIMO) to release data that may further influence clinical practice and provide further clinical evidence on how we can better protect the patients with CAT.


Today, we are delighted to welcome Bayer as our new sponsor, that supports us with an unrestricted educational grant. Welcome! 

Would you like to read more about Bayers’s activity in CAT? Click here. 

Rate this article

Login or register to leave a comment or rate this article